Yan Ji

About Yan Ji

Scientific and strategic leader in drug discovery and development of a broad variety of modalities (small molecules, biologics, cell therapy, radioligand therapy) across multiple therapeutic areas (oncology, immunology, neuroscience, cardiovascular and metabolic disease)• Expert in Clinical Pharmacology, pharmacokinetics & pharmacodynamics, modeling and simulation, DMPK, and model-informed drug development• Extensive experience of worldwide submission and registration including IND, EoP2, NDA, and BLA

Experience

1. Director, Pk Sciences & Clinical Pharmacology

   Novartis

   Oct 2016 — Present

   Clinical pharmacology & PKS project lead for broad modalities (small molecules, antibodies, CAR-T, radioligand therapy) from discovery and IND to registration and life-cycle management in oncology and immunology-Clin Pharm & DMPK lead for global NDA/sNDA submission and BLA submission in oncology and immunology-Clin Pharm & PKS lead for a disease area in oncology

Education

• University at Buffalo

  Ph.D., Pharmaceutical Sciences

  2000 — 2005

• Sichuan Univeristy- Huaxi School of Medicine

  M.S., Biochemistry

• Sichuan University

  B.S., Chemistry

• The University of Toledo

  M.S., Pharmacology

  1998 — 2000

Skills

• Drug Development
• Pk/Pd Modeling and Simulation
• Pharmacokinetics
• Clinical Development
• Dmpk
• Pk
• Nonmem
• Clinical Research
• Clinical Pharmacology
• Translational Medicine
• Pk/Pd
• Small Molecules
• Biologics
• Biologics Pk/Pd
• S-Plus
• Adme
• Drug Discovery
• Clinical Study Design
• Nda
• Monoclonal Antibodies
• R
• New Drug Application (Nda)